A Single-arm, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Endostar Subcutaneous Injection in Chinese Advanced NSCLC Patients

Trial Profile

A Single-arm, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Endostar Subcutaneous Injection in Chinese Advanced NSCLC Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Endostatin (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Jiangsu Simcere Pharmaceutical
  • Most Recent Events

    • 27 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top